New digital platform and MicroScan transducers offer unprecedented imaging capabilities including color doppler and cardiac strain analysis.
Toronto, Ontario – October 7, 2008 - The Vevo 2100 was released for sale in the preclinical market today in North America and Europe. For the first time, high resolution images with edge to edge clarity and dynamic focusing are possible and will allow small animal researchers to scan measure and quantify with ease. “The Vevo 2100 represents a world breakthrough in imaging technology, a tremendous advance in life science imaging and a breakthrough in ultrasound technology” said Tom Little, President and Chief Executive Officer of VisualSonics. “Being able to include color flow imaging, advanced transducers and a more robust analysis package will not only benefit our existing core customer base, it will expand beyond that to a include a range of new markets and indications”.
Non-invasive, realtime in vivo imaging with high resolution has defined VisualSonics contribution to small animal micro-imaging. Innovation has continued with the Vevo 2100. There have been a number of technological firsts, “Our engineering team has developed the world’s first high frequency linear array transducers and has developed strong intellectual property in this area” remarked Desmond Hirson, Vice President of Engineering.
The Vevo 2100 provides researchers the flexibility to conduct longitudinal studies on a range of models including the mouse, rat, zebra fish, and rabbit. These models play an important role in translating research from the laboratory to the clinic. “The wide field of view, broad depth of focus and multiple focal zones will allow researchers to image structures never seen before; this is really exciting” stated Dr. Stuart Foster, Founder and Chief Scientific Officer at VisualSonics.
About VisualSonics
VisualSonics is the world’s leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company’s enabling technology allows researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research into cardiovascular disease, cancer, and developmental biology including genetic research, phenotypic study and drug development. Only VisualSonics platforms combine high-resolution, realtime in vivo imaging at reasonable cost with ease-of-use, portability and no negative biological effects. More information on VisualSonics can be found at www.visualsonics.com.